See more : Concordia Maritime AB (publ) (CCOR-B.ST) Income Statement Analysis – Financial Results
Complete financial analysis of AzurRx BioPharma, Inc. (AZRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AzurRx BioPharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Thumzup Media Corporation (TZUP) Income Statement Analysis – Financial Results
- Bank of Utica (BKUTK) Income Statement Analysis – Financial Results
- Ares Acquisition Corporation Re (AAC-WT) Income Statement Analysis – Financial Results
- GACM Technologies Limited (GATECH.BO) Income Statement Analysis – Financial Results
- Salasar Techno Engineering Limited (SALASAR.NS) Income Statement Analysis – Financial Results
AzurRx BioPharma, Inc. (AZRX)
About AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Brooklyn, New York and currently employs 12 full-time employees. The firm is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The firm's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5,888.00B | 8.68M | 4.99M | 2.40M | 2.50M | 1.40M |
| General & Administrative | 7.29M | 6.06M | 8.24M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.29M | 6.06M | 8.24M | 0.00 | 0.00 | 0.00 |
| Other Expenses | 20,544.76B | 0.00 | 210.00K | 7.69M | 4.13M | -4.73M |
| Operating Expenses | 26,432.77B | 14.74M | 13.43M | 10.08M | 6.63M | -3.33M |
| Cost & Expenses | 26,432.77B | 14.74M | 13.43M | 10.08M | 6.63M | 4.73M |
| Interest Income | 484.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5,840.61B | 433.94K | 101.85K | 875.20K | 5.94M | 1.59M |
| Depreciation & Amortization | 37.80K | 1.02M | 798.45K | 754.00K | 734.50K | 733.60K |
| EBITDA | -26,830.85B | -13.72M | -12.63M | -9.47M | -7.92M | -3.61M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -26,432.77B | -14.74M | -13.43M | -10.08M | -6.63M | -4.73M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6,238.70B | -433.94K | -101.85K | -1.02M | -7.97M | -1.20M |
| Income Before Tax | -32,671.47B | -15.18M | -13.53M | -11.10M | -14.59M | -5.93M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -398.08B | 0.00 | 0.00 | -140.00K | -2.03M | 386.11K |
| Net Income | -32,671.47B | -15.18M | -13.53M | -11.10M | -14.59M | -5.93M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -5.90M | -6.77 | -8.77 | -10.44 | -22.43 | -6.16 |
| EPS Diluted | -5.90M | -6.77 | -8.77 | -10.44 | -22.43 | -6.16 |
| Weighted Avg Shares Out | 5.53M | 2.24M | 1.54M | 1.06M | 650.48K | 963.11K |
| Weighted Avg Shares Out (Dil) | 5.53M | 2.24M | 1.54M | 1.06M | 650.48K | 963.11K |
AzurRx BioPharma Announces Exclusive Worldwide License Agreement with First Wave Bio for Use of Proprietary Niclosamide Formulations to Treat Immune Checkpoint Inhibitor-Associated Colitis and COVID-19 Gastrointestinal Infections
AzurRx BioPharma Announces First Patients Dosed in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
AzurRx BioPharma Requests Protocol Amendment to Phase 2b OPTION 2 Study of MS1819 in Cystic Fibrosis Patients
AzurRx BioPharma Identifies Asymchem as Potential Partner of Choice for MS1819 Phase 3 Clinical Trial Drug Production
AzurRx BioPharma Provides Insight into Drawbacks of Using Porcine Products in Production of Pharmaceuticals and Medicinals, Offers Update on Efforts to Produce Synthetic Alternatives
COVID-19 Diagnostic Kits and Therapy Market to Reach $13.9 Billion by 2025- Exclusive Report by Meticulous Research®
A Blue Ocean Robotics és UVD Robots leányvállalata bekerült a Robotics Business Review által az 50 legnagyobb hatású tevékenységet végző robotikai vállalatról összeállított listába
Blue Ocean Robotics and its UVD Robots Recognized as Top 50 Most Influential Robotics Company by Robotics Business Review
Analyzing Taro Pharmaceutical Industries (NYSE:TARO) & AzurRx BioPharma (NYSE:AZRX)
Source: https://incomestatements.info
Category: Stock Reports